Gilteritinib plus FLAI chemo for FLT3-positive AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have acute myeloid leukemia (AML) with a FLT3 mutation (a specific gene change).
- You have not started treatment for AML yet.
- Your heart, kidneys, and liver are working well enough (your doctor will test these).
- You can be active and care for yourself (performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a new combination of three drugs (gilteritinib, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) that no longer responds to azacitidine and venetoclax. The goal is to see if this triple therapy can help achieve remission and improve outcomes.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This study looks at how well new AML medicines work in everyday medical practice, outside of clinical trials. If you are starting a newer AML drug like gilteritinib, an IDH inhibitor, oral azacytidine, or others, you may be able to join.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.